• Explore /
  • Poster
  • / Alpha fetoprotein (AFP) response and efficacy outcomes in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).

Alpha fetoprotein (AFP) response and efficacy outcomes in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).

Abstract Poster

Authors

null

Robin Kate Kelley

University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

Robin Kate Kelley , Lorenza Rimassa , Baek-Yeol Ryoo , Joong-Won Park , Jean-Frédéric Blanc , Stephen Lam Chan , Vincenzo Dadduzio , Thomas Cheung Yau , Suvajit Sen , David W. Markby , Rajesh Kaldate , Anthony B. El-Khoueiry , Ann-Lii Cheng , Tim Meyer , Ghassan K. Abou-Alfa

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT01908426

Citation

J Clin Oncol 37, 2019 (suppl 4; abstr 423)

DOI

10.1200/JCO.2019.37.4_suppl.423

Abstract #

423

Poster Bd #

N3

Abstract Disclosures

Similar Posters

First Author: Robin Kate Kelley

First Author: Ghassan K. Abou-Alfa

First Author: Philippe Merle

First Author: Mathias Earl Palmer